Abstract: Cervical cancer remains the leading cause of cancer-related mortality worldwide and represents a major global health challenge. Recently, the overall survival of cervical cancer patients has been significantly prolonged with the development of targeted therapy and immunotherapy, especially with the application of the anti-angiogenic drug, bevacizumab. Nevertheless, a small subset of these patients showed a poor response to targeted therapy, and the underlying mechanisms remain to be elucidated. Molecular subtyping classifies cervical cancer based on gene expression patterns. It can further distinguish the eligible population and improve the clinical management of cervical cancer patients. Here, we summarize recent advances in translational research outcomes, the results of clinical trials of targeted therapy and immunotherapy, and the molecular subtypes of cervical cancer.